Scandinavian ChemoTech´s subsidiary Vetiqure participates in its first veterinarian conference in the US

As previously announced Vetiqure is now commencing its marketing in the US starting with the veterinarian conference KVMA in Louisville, KY September 24-26

Please come and meet Vetiqure and DCG INT LLC (a US based consultancy firm) at the KVMA conference in Louisville starting today, where we will introduce and demonstrate our device vetIQure™. vetIQure™ is the Next Generation of electrochemotherapy systems for safe and easy cancer treatment.

The vetIQure™ system is built on the latest technology called Tumour Specific Electroporation™ (TSE), used by veterinarians and ideal for small as well as larger animals.

TSE is using a new and revolutionary Dynamic- and Multi-directional pulse technology which makes it very easy to treat any animal while minimizing the risk of burns or over-treatments.

If you are interested in a one-on-one demonstration, please visit us at our booth to schedule a time for a private demo.

You find us in booth #19!

About KVMA
The Kentucky Veterinary Medical Association (KVMA) established in 1911, is a proactive group of more than 1000 professionals representing many facets of veterinary medicine – clinical practice, public health, regulatory, academe, and the military. Members are dedicated to working together improve the veterinary profession in Kentucky.  Through their combined efforts, KVMA can build stronger relationships with the public and policy makers by expanding their understanding of and appreciation for the profession.

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.